Calabrese Giulio, Manfredi Guido, Maida Marcello F, Mandarino Francesco V, Shahini Endrit, Pugliese Francesco, Cecinato Paolo, Laterza Liboria, Sinagra Emanuele, Sferrazza Sandro
Department of Gastroenterology and Endoscopy, ARNAS Civico-Di Cristina-Benfratelli, Palermo 90127, Sicilia, Italy.
Department of Gastroenterology and Digestive Endoscopy, Ospedale Maggiore, Crema 26013, Italy.
World J Gastrointest Endosc. 2024 Aug 16;16(8):439-444. doi: 10.4253/wjge.v16.i8.439.
In this editorial, we explore the challenges of managing noncurative resections in early gastric cancer after endoscopic submucosal dissection (ESD), starting from the consideration recently made by Zhu . Specifically, we evaluate the management of eCura C1 lesions, where decisions regarding further interventions are pivotal yet contentious. Collaboration among endoscopists, surgeons, and pathologists is underscored to refine risk assessment and personalize therapeutic management. Recent advancements in ESD techniques and interdisciplinary collaboration offer opportunities for outcome optimization in managing eCura C1 lesions. Moreover, despite needing further clinical validation, molecular biomarkers have emerged as promising tools for enhancing prognostication. This manuscript highlights the ongoing research attempts to define treatment paradigms effectively and evaluates the potential of emerging options, ultimately aiming to improve patient care and outcomes in this complex clinical scenario.
在这篇社论中,我们从朱最近的思考出发,探讨内镜黏膜下剥离术(ESD)后早期胃癌非根治性切除的管理挑战。具体而言,我们评估eCura C1病变的管理,其中关于进一步干预的决策至关重要但存在争议。强调内镜医师、外科医生和病理学家之间的合作,以完善风险评估并实现治疗管理的个性化。ESD技术的最新进展和跨学科合作提供了优化eCura C1病变管理结果的机会。此外,尽管需要进一步的临床验证,但分子生物标志物已成为增强预后预测的有前景的工具。本文强调了正在进行的有效定义治疗模式的研究尝试,并评估新兴选择的潜力,最终旨在改善这种复杂临床情况下的患者护理和治疗结果。